Technical Analysis for CRDF - Cardiff Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 9.72 | 5.88% | 0.54 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CRDF trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 5.88% | |
| Wide Bands | Range Expansion | 5.88% | |
| Fell Below 200 DMA | Bearish | -3.86% | |
| Wide Bands | Range Expansion | -3.86% | |
| Crossed Above 200 DMA | Bullish | -12.43% | |
| Wide Bands | Range Expansion | -12.43% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Lower Bollinger Band Support | about 12 hours ago | |
| Down 10% | about 13 hours ago | |
| 60 Minute Opening Range Breakdown | about 14 hours ago | |
| Fell Below Lower Bollinger Band | about 14 hours ago | |
| Down 5% | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/25/2021
Cardiff Oncology, Inc. Description
Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Oncology Lymphoma Cancer Treatments Prostate Cancer Phosphate Chemotherapy Acute Myeloid Leukemia Antineoplastic Drugs Leukemia Targeted Therapy Colorectal Cancer Takeda Pharmaceutical Company Advanced Solid Tumors Resistant Prostate Cancer Solid Tumor Cancers Adenosine Leukemias Metastatic Colorectal Cancer Metastatic Castration Resistant Prostate Cancer Chemotherapies Nektar Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.5 |
| 52 Week Low | 0.701 |
| Average Volume | 2,074,118 |
| 200-Day Moving Average | 10.98 |
| 50-Day Moving Average | 13.73 |
| 20-Day Moving Average | 11.59 |
| 10-Day Moving Average | 10.28 |
| Average True Range | 1.17 |
| ADX | 21.55 |
| +DI | 15.28 |
| -DI | 38.10 |
| Chandelier Exit (Long, 3 ATRs ) | 11.44 |
| Chandelier Exit (Short, 3 ATRs ) | 11.76 |
| Upper Bollinger Band | 14.54 |
| Lower Bollinger Band | 8.65 |
| Percent B (%b) | 0.18 |
| BandWidth | 50.84 |
| MACD Line | -1.10 |
| MACD Signal Line | -1.05 |
| MACD Histogram | -0.0561 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.08 | ||||
| Resistance 3 (R3) | 11.84 | 10.83 | 11.68 | ||
| Resistance 2 (R2) | 10.83 | 10.23 | 10.94 | 11.55 | |
| Resistance 1 (R1) | 10.27 | 9.86 | 10.55 | 10.51 | 11.42 |
| Pivot Point | 9.26 | 9.26 | 9.40 | 9.37 | 9.26 |
| Support 1 (S1) | 8.70 | 8.66 | 8.98 | 8.94 | 8.02 |
| Support 2 (S2) | 7.69 | 8.29 | 7.80 | 7.89 | |
| Support 3 (S3) | 7.13 | 7.69 | 7.76 | ||
| Support 4 (S4) | 7.37 |
